Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 4

Restless leg syndrome: is it a real problem?

Authors Paul E Cotter, Shaun T O’Keeffe

Published 15 December 2006 Volume 2006:2(4) Pages 465—475

Paul E Cotter, Shaun T O’Keeffe
Department of Geriatric Medicine, Galway University Hospitals, Galway, Ireland
Abstract: Restless legs syndrome (RLS) is a common condition that is frequently unrecognized, misdiagnosed and poorly managed. It is characterized by uncomfortable sensations deep in the legs developing at rest that compel the person to move; symptoms are worst at night and sleep disturbance is common. RLS occurs in 7%–11% of the population in Western countries, and many such people experience troublesome symptoms. Primary RLS is familial in up to two thirds of patients. RLS may also be secondary to a number of conditions including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy. Secondary RLS is most common in those presenting for the first time in later life. The pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and impaired dopaminergic neurotransmission in the subcortex of the brain. RLS is very responsive to dopaminergic therapies. Rebound of RLS symptoms during the early morning and development of severe symptoms earlier in the day (augmentation) are problematic in those treated for a prolonged period with levodopa. Consequently, dopamine agonists have become first line treatment. Anti-convulsant medications and opioids are helpful in some patients. Correction of underlying problem wherever possible is important in the management of secondary RLS.
Keywords: Restless legs syndrome; sleep; iron deficiency; neuropathy

Download Article [PDF] 

Readers of this article also read:

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008

Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

Daniela A Bota, Annick Desjardins, Jennifer A Quinn, Mary L Affronti, Henry S Friedman

Therapeutics and Clinical Risk Management 2007, 3:707-715

Published Date: 15 November 2007

The use of antithrombotics in patients presenting with stroke and atrial fibrillation

Carl Burgess, Tristram Ingham, Martin Woodbridge, Mark Weatherall, Michael Nowitz

Therapeutics and Clinical Risk Management 2007, 3:491-498

Published Date: 15 July 2007

Acute migraine: Current treatment and emerging therapies

Arun A Kalra, Debra Elliott

Therapeutics and Clinical Risk Management 2007, 3:449-459

Published Date: 15 July 2007

Effect of patient-specific factors on weekly warfarin dose

Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Therapeutics and Clinical Risk Management 2007, 3:499-504

Published Date: 15 July 2007

Abatacept in the treatment of rheumatoid arthritis

Edward M Vital, Paul Emery

Therapeutics and Clinical Risk Management 2006, 2:365-375

Published Date: 15 December 2006

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006

Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series

Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare

Therapeutics and Clinical Risk Management 2006, 2:329-334

Published Date: 15 September 2006